Response to "Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2".

Du, Yin-Xiao; Chen, Xiao-Ping

Du, Yin-Xiao; Chen, Xiao-Ping.

Du YX; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Chen XP; Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, Hunan, China.

Clin Pharmacol Ther ; 108(2): 190, 2020 08.

Article in English | MEDLINE | ID: covidwho-1384147

Subject(s)

Betacoronavirus; Coronavirus Infections; Pandemics; Pneumonia, Viral; Severe acute respiratory syndrome-related coronavirus; Amides; COVID-19; Humans; Pyrazines; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Severe acute respiratory syndrome-related coronavirus / Pandemics / Betacoronavirus Limits: Humans Language: English Journal: Clin Pharmacol Ther Year: 2020 Document Type: Article Affiliation country: CPT.1878

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google